Astrazeneca: An overview
Astrazeneca is a leading pharmaceutical company formed in 1999 through merger of Astra AB of Sweden and Zeneca group PLC of UK (www.astrazeneca.com). The world pharmaceuticals market was valued at $492 billion in 2004 (Astrazeneca annual report, 2004). Moreover with Astrazeneca pumping in almost $3.8 billion into research and development for new drugs in 2004 at the rate of $15 million per working day makes it an interesting and an ideal entity to analyse (Astrazeneca annual report, 2004).
In addition to the above facts, Astrazeneca being a pioneer in its field will definitely be an ideal entity to study and analyze. Companies in the big league are expected to adhere to the highest
References:  Accounting Standards Board, 1999. Statement of principles for financial reporting, London: ASB.  Flint, D. 1982. A true and fair view. Great Britain. Gee & Co (publishers) limited.  Study Group, 1973.Objectives of financial statements. Newyork. American institute of certified accountants.  Jameson, M. 1988.A practical guide to creative accounting. Guildford. Biddles limited.  Griffiths, I. 1995.New creative accounting. London. Macmillian.  Atril, P and Maclaney, E.2002.3dr Ed. Financial accounting for Non-specialists. Harlow. Pearson Education limited.  Anon,2005.www.astrazeneca.com.(online).accessed on 12 November  Anon, 2001 Statement of accounting concept. Accounting standard review board.  Anon, 2005. Annual report and form 20F information. Astrazeneca.